Clinical Trial Update: Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an anti-von Willebrand Factor nanobody for safety and efficacy in acquired thrombotic thrombocytopenic purpura has completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• anti-von Willebrand Factor nanobody

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Acquired Thrombotic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED | Results posted: 2019-05-29